491 related articles for article (PubMed ID: 36109798)
21. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
22. Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
Li J; Huo S; Zhang R; Shi C; Sun N; Liu Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):562-572. PubMed ID: 35753726
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.
Panwoon C; Seubwai W; Thanee M; Sangkhamanon S
PLoS One; 2024; 19(6):e0305252. PubMed ID: 38857246
[TBL] [Abstract][Full Text] [Related]
24. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
25. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
26. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
28. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
30. Association of Elevated C-Reactive Protein with Worsened Outcomes in Different Histologies of Renal Cortical Tumors: Analysis of the INMARC Registry.
Saitta C; Afari JA; Patil D; Tanaka H; Yuen KL; Wang L; Cortes J; Liu F; Mahmood M; Matian J; Mansour M; Puri D; Cerrato C; Nguyen MV; Hakimi K; Kobayashi M; Fukuda S; Meagher MF; Fujii Y; Master V; Derweesh IH
Clin Genitourin Cancer; 2024 Jun; 22(3):102098. PubMed ID: 38733897
[TBL] [Abstract][Full Text] [Related]
31. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of a ferroptosis-related signature for prediction of the prognosis and tumor microenvironment in patients with chromophobe renal cell carcinoma.
Liu S; Yao Y; Hou M; Mei J; Sun L; Zhang G
BMC Cancer; 2023 Nov; 23(1):1079. PubMed ID: 37940859
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study.
Fleury R; Bertail T; Bensalah K; Bernhard JC; Audenet F; Waeckel T; Parier B; Champy C; Olivier J; Doumerc N; Tricard T; Branger N; Bruyere F; Neuville P; Surlemont L; Alexandre Long J; Fontenil A; Vallee M; Roupret M; Boissier R; Jacques Patard J; Durand M; Ouzaid I; Rouget B; Durand X; Joncour C; Belas O; Denise Gomez F; Bigot P; Khene ZE;
Eur Urol Open Sci; 2024 Apr; 62():123-130. PubMed ID: 38496822
[TBL] [Abstract][Full Text] [Related]
34. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
35. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
36. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma.
Lee CH; Jung SJ; Seo WI; Chung JI; Lee DS; Jeong DH; Jeon Y; Choi I
Int J Immunopathol Pharmacol; 2022; 36():3946320221125588. PubMed ID: 36083857
[TBL] [Abstract][Full Text] [Related]
37. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
38. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
39. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.
Liu K; Huang Y; Xu Y; Wang G; Cai S; Zhang X; Shi T
Cancer Immunol Immunother; 2023 Aug; 72(8):2557-2572. PubMed ID: 37046008
[TBL] [Abstract][Full Text] [Related]
40. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
